tripterygium wilfordii

PreclinicalSmall molecule

tripterygium wilfordii is one of 63 small molecule programs targeting Focal Segmental Glomerulosclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal Segmental GlomerulosclerosisActive, not recruiting

Membranous NephropathyActive, not recruiting

Autosomal Dominant Polycystic Kidney DiseaseActive, not recruiting

ProspectiveTerminated

Focal Segmental GlomerulosclerosisPreclinical

Active, not recruiting

Membranous NephropathyPreclinical

Active, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePreclinical

Active, not recruiting

ProspectivePreclinical

Terminated

Competition

Competitive Landscape

31 competitors in Prospective

#DrugCompanyPhaseTrials

Tnkase

Roche

Approved

1 2

Zeposia

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 3

Nexavar

Bayer

Phase 3

2 4

Venclexta

AbbVie

Phase 3

2 5

Cytosar

Teva

Phase 3

1 6

Xiidra

BBausch Health Americas, Inc.

Approved

1 7

Mulpleta

IItalian Network for Tumor Biotherapy Foundation

Approved

1 8

Beyfortus

BeiGene

Phase 2

1 9

Imbruvica

PPharmacyclics LLC.

Phase 2

1 10

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Focal Segmental Glomerulosclerosis1 trial

Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis

Completed·NNanjing University School of Medicine·N/A·NCT00801463·67 enrolled

Prospective1 trial

Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Terminated·NNanjing University School of Medicine·N/A·NCT00885547·90 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Terminated·ZZhi-Hong Liu, M.D.·N/A·NCT00801268·300 enrolled

Pterygium1 trial

Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Completed·PPeking Union Medical College Hospital·Phase 4·NCT03589833·504 enrolled

Membranous Nephropathy1 trial

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

Completed·ZZhi-Hong Liu, M.D.·N/A·NCT01161459·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for tripterygium wilfordii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tripterygium wilfordii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tripterygium wilfordii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhi-Hong Liu, M.D. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhi-Hong Liu, M.D.

tripterygium wilfordii

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Focal Segmental Glomerulosclerosis1 trial

Prospective1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

Pterygium1 trial

Membranous Nephropathy1 trial

References

Drug Info

Quick Facts

Related News